Sorafenib has dual anti-tumor effects (Ortega-Muelas et al., 2021), which can not only directly inhibit the proliferation of tumor cells by mediating RAF/MEK/ERK pathway but also cut off the nutrition of tumor cells through inhibiting the formation of new blood vessels (Spirli et al., 2012). This evidence concerns the gene MAP2K7 and neoplasm.